Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 5/20 | 0.34 |
| ▸ | NOS2 | P35228 | 4/20 | 0.34 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15995454 | 0.84 | CA2 (0.57) | CA2CA1MAPK1NOS1CPN1 | |
| SCHEMBL16013208 | 0.76 | DDAH1 (0.31) | NOS1NOS2DDAH1CYP2C19 | |
| Hydrochloric Acid SCHEMBL28639611 | 0.76 | CA1 (0.34) | CA2CA1NOS1NOS2CPB2 | |
| SCHEMBL24295447 | 0.75 | CTSL (0.34) | CA2CA1NOS1DDAH1 | |
| SCHEMBL376915 | 0.74 | CA2 (1.00) | CA2CA1MAPK1MEN1KMT2A | |
| SCHEMBL7038841 | 0.74 | CA2 (1.00) | CA2CA1MAPK1MEN1KMT2A | |
| SCHEMBL277393 | 0.72 | CA2 (0.87) | CA2CA1MAPK1 | |
| SCHEMBL9542331 | 0.72 | CA2 (0.95) | CA2CA1MAPK1MEN1KMT2A | |
| SCHEMBL6445932 | 0.72 | CA2 (0.95) | CA2CA1MAPK1MEN1KMT2A | |
| SCHEMBL5446281 | 0.72 | CA2 (0.72) | CA2CA1MAPK1CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20250186627-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-12 | — | — | US | disclosed |
| US-20250161501-A1 | Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-05-22 | — | — | US | disclosed |
| WO-2025054727-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-20 | — | — | WO | disclosed |
| US-12246076-B2 | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-11 | — | — | US | disclosed |
| EP-4499663-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | Provincial Health Services Authority (CA) | 2025-02-05 | — | — | EP | disclosed |
| EP-4486756-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | Provincial Health Services Authority (CA) | 2025-01-08 | — | — | EP | disclosed |
| CN-119213011-A | Radiolabeled compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders | 省卫生服务机构 | 2024-12-27 | — | — | CN | disclosed |
| US-20240123099-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-04-18 | — | — | US | disclosed |
| WO-2023178449-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023164775-A1 | RADIOLABELED COMPOUNDS TARGETNG THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023133645-A1 | RADIOLABELED COMPOUNDS FOR IMAGING OF FIBROBLAST ACTIVATION PROTEIN (FAP) AND TREATMENT OF FAP-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186627-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FSHR, ESRRA, ESRRG | CA2 2307/4885CA1 1092/4885MAPK1 3051/4885 |
| US-20250161501-A1 | Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders | FAP, FIBP, FGFR1 | CA2 888/4885CA1 3221/4885MAPK1 1712/4885 |
| US-12246076-B2 | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | GRPR, NPY5R, NPY2R | CA2 1162/4885CA1 209/4885MAPK1 3874/4885 |
| US-20240123099-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | CA2 1162/4885CA1 209/4885MAPK1 3874/4885 |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | CA2 1083/4885CA1 210/4885MAPK1 4024/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | CA2 311/4885CA1 104/4885MAPK1 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.